You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.
The method can be used with isothermal amplification and paper-based readouts to detect infectious disease drug resistance in low-resource areas.
BioMérieux had alleged infringement of two of its patents associated with nucleotide sequences to detect HIV-1 subtypes.
NIH Director Francis Collins describes at Forbes how the agency is working with the Bill & Melinda Gates Foundation to develop gene-based treatments for sickle cell disease and HIV for sub-Saharan Africa.
The firm saw strong increases in international HIV sales of its OraQuick HIV Self-Test product in the quarter.
China remains a key strategic market for Roche, and it said that it has multiple assays for 2019-nCoV coronavirus for research-use only.
Within diagnostics, the firm posted molecular diagnostics revenues of $178.5 million, up 9 percent from $164.3 million in fiscal Q1 2019.
The clearance covers tests made by the firm's joint venture for manufacturing, CoSara Diagnostics, in its facility in Ranoli, India.
The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.